Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy...
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 4, 2023--
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 4, 2023--